Drug Trial Radar · NCT02069899
A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody
Last checked: Nov 20, 2026Latest source record: Jun 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
58
Actual
Start
Aug 4, 2014
Primary completion
May 18, 2021
Study completion May 18, 2021
Sponsor
- Lead sponsor
- Swedish Orphan BiovitrumIndustry
- Sponsor type
- Industry
- Collaborators
- Seventh Framework Programme
- First posted
- Feb 24, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
International, multicenter, long-term, follow-up study that will enrol HLH participants who have received emapalumab in previous clinical trials, in the context of the clinical development program for emapalumab or under compassionate use (CU).
Conditions
- Hemophagocytic Lymphohistiocytosis
Interventions
EmapalumabDrug
Treatment with emapalumab is not planned for all enrolled participants. For participants who will continue receiving emapalumab in the context of this study (NI-0501-05), the dose and timing will be either carried forward from the last administered emapalumab dose as part of the parent study in which the participant was enrolled, or an adjusted dose will be administered, if necessary.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Event (AE)Time frame: From the date of enrollment in this study up to 1 year either after HSCT or after the last administration of emapalumab (maximum duration: 639 days)
Locations
16 sites in 5 countries. Site status is shown where the registry gives one.
Spectrum Health Helen Devos Children's Hospital
Grand Rapids, Michigan
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Cincinnati Children's Hospital - Division of Immunobiology
Cincinnati, Ohio
Cincinnati Children's Hospital
Cincinnati, Ohio
Texas Children's Cancer Center
Houston, Texas
Hôpital Necker-Enfants Malades
Paris, France
Fondazione MBBM c/o Ospedale San Gerardo Clinica Pediatrica
Monza, Italy
Azienda Ospedaliera Padova
Padova, Italy
Ospedale Pediatrico Bambino Gesu - UO Reumatologia
Rome, Italy
Ospedale Pediatrico Bambino Gesu
Rome, Italy
Ospedale della Donna e del Bambino - U.O.C. Oncoematologia Pediatrica
Verona, Italy
Hospital Universitario Vall d'Hebron Servei de Hematologia i Oncologia
Barcelona, Spain
Sant Joan de Déu Hospital - Pediatric Rheumatology Department
Barcelona, Spain
Hospital Universitario Niño Jesús Servicio de Hemato-Oncología Pediátrica
Madrid, Spain
UCL Institute of Child Health Great Ormond Street Hospital
London, United Kingdom
Great Ormond Street Hospital - Department of Haematology
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.